Natera Inc NTRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if NTRA is a good fit for your portfolio.
News
-
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
-
Natera Reports First Quarter 2024 Financial Results
-
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
-
Natera to Report its First Quarter 2024 Results on May 9
-
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
-
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
-
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
-
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
Trading Information
- Previous Close Price
- $107.31
- Day Range
- $106.13–108.49
- 52-Week Range
- $36.94–108.49
- Bid/Ask
- $108.24 / $108.36
- Market Cap
- $13.30 Bil
- Volume/Avg
- 621,116 / 1.5 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 10.24
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 3,018
- Website
- https://www.natera.com
Comparables
Valuation
Metric
|
NTRA
|
GH
|
SLGC
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 16.24 | 45.93 | 0.80 |
Price/Sales | 10.24 | 4.98 | 4.80 |
Price/Cash Flow | — | — | — |
Price/Earnings
No chart available
Financial Strength
Metric
|
NTRA
|
GH
|
SLGC
|
---|---|---|---|
Quick Ratio | 3.83 | 6.11 | 17.08 |
Current Ratio | 4.12 | 6.54 | 17.79 |
Interest Coverage | −30.10 | −198.43 | — |
Quick Ratio
NTRA
GH
SLGC
Profitability
Metric
|
NTRA
|
GH
|
SLGC
|
---|---|---|---|
Return on Assets (Normalized) | −14.06% | −17.37% | −18.10% |
Return on Equity (Normalized) | −27.11% | −213.40% | −20.69% |
Return on Invested Capital (Normalized) | −17.95% | −22.39% | −23.76% |
Return on Assets
NTRA
GH
SLGC
Diagnostics & Research Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Tbgkqtnfy | Frtgp | $228.7 Bil | |
DHR
| Danaher Corp | Nbqtbfpd | Rxnpfv | $195.1 Bil | |
A
| Agilent Technologies Inc | Ggbmznqr | Pzzyb | $45.2 Bil | |
IQV
| IQVIA Holdings Inc | Qxfdvnpfd | Tllwt | $42.1 Bil | |
IDXX
| IDEXX Laboratories Inc | Ktcgxbvygh | Hzrcv | $41.5 Bil | |
MTD
| Mettler-Toledo International Inc | Zhwzfdpx | Mvkjbp | $32.5 Bil | |
ICLR
| Icon PLC | Zjgdkdshb | Xfbscg | $26.6 Bil | |
WAT
| Waters Corp | Tcnwckwrr | Hfwq | $21.5 Bil | |
ILMN
| Illumina Inc | Xrrddfck | Hwbhdcg | $18.3 Bil | |
LH
| Laboratory Corp of America Holdings | Pwcvvwkkx | Nwpjw | $18.0 Bil |